The Excitement Surrounding Immunotherapies for Melanoma
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the excitement surrounding immunotherapies for the treatment of patients with melanoma.
Clinical Pearls
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the excitement surrounding immunotherapies for the treatment of patients with melanoma.
- By taking away the PD-1/PD-L1 break, which is relevant inside the tumor, it is possible to study a tumor and determine if the PD-1/PD-L1 regulatory pathway was turning off T cells
- PD-1/PD-L1 inhibitors are easier to study than older immunotherapies that require turning on the immune system
- Researchers are able to determine who will respond to PD-1/PD-L1 inhibitors and how to intervene in those patients that will not
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
